Man Group
NMTR

Man Group’s 9 Meters Biopharma NMTR Stock Holding History

Man Group’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,959
Closed -$13K – 2322
2022
Q3 		$13K Buy
+2,959
New +$14.7K ﹤0.01% 1966
2021
Q1 		– Sell
-704
Closed -$12K – 2044
2020
Q4 		$12K Buy
+704
New +$11.7K ﹤0.01% 1804

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Man Group's NMTR Position: Q4 2022 in Review

Man Group sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 2,959 shares — an estimated $13K sold.

Man Group first reported a position in NMTR in Q4 2020 and held it in 2 quarters. The position peaked at $13K in Q3 2022. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

  • Man Group reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
  • Man Group sold 2,959 9 Meters Biopharma shares in Q4 2022, an estimated $13K.
  • Man Group first reported a position in 9 Meters Biopharma in Q4 2020 and held it in 2 quarters.
  • Man Group's 9 Meters Biopharma position peaked at $13K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.